New Brighton, MN, United States of America

Raji A Shankar


Average Co-Inventor Count = 2.0

ph-index = 2

Forward Citations = 86(Granted Patents)


Company Filing History:


Years Active: 1996-1997

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Raji A Shankar: Innovator in Immunotherapy

Introduction

Raji A Shankar is a notable inventor based in New Brighton, MN (US). He has made significant contributions to the field of immunotherapy, particularly in the culturing of leukocytes. With a total of 2 patents, his work is paving the way for advancements in cancer treatment and immune response enhancement.

Latest Patents

Raji A Shankar's latest patents include an "Immunotherapy protocol of culturing leukocytes in the presence of interleukin-2" and a "Method of culturing leukocytes." The immunotherapy protocol involves culturing leukocytes in a hollow fiber cartridge perfusion system for at least four days. This method achieves a harvest yield of at least 100% of leukocytes compared to the initial number of cells present in the hollow cartridge. The leukocytes produced exhibit lytic activity that is at least equal to that of cells grown in a static culturing system. Similarly, the method for culturing leukocytes also emphasizes the use of a hollow fiber cartridge perfusion system to achieve optimal yields and lytic activity.

Career Highlights

Raji A Shankar is currently associated with Endotronics, Inc., where he continues to innovate in the field of immunotherapy. His work is characterized by a commitment to improving the efficacy of leukocyte cultures, which is crucial for developing effective immunotherapeutic strategies.

Collaborations

Raji collaborates with Georgiann B Melink, contributing to the advancement of their shared goals in immunotherapy research.

Conclusion

Raji A Shankar's contributions to immunotherapy through his innovative patents highlight his role as a key inventor in the field. His work not only enhances our understanding of leukocyte culturing but also holds promise for future therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…